▁In 10.375
▁a 6.5078125
▁ground 10.15625
bre 3.521484375
aking 0.007762908935546875
▁development 4.03515625
, 1.4716796875
▁British 7.7890625
▁Bi 9.1953125
ote 2.568359375
ch 0.51123046875
▁Pl 7.59375
c 4.44921875
▁has 2.91796875
▁un 5.39453125
ve 1.0322265625
iled 0.2113037109375
▁its 3.478515625
▁highly 7.94140625
▁anticip 1.7783203125
ated 0.049468994140625
▁cancer 11.0546875
▁drug 3.96484375
, 1.7646484375
▁Mar 7.4765625
im 9.28125
ast 9.6875
at 5.609375
, 1.6875
▁show 8.3828125
c 0.40380859375
asing 0.2413330078125
▁prom 7.05859375
ising 0.305419921875
▁results 2.474609375
▁in 2.283203125
▁early 5.1015625
▁clin 1.6875
ical 0.0120086669921875
▁tri 0.61767578125
als 0.0016498565673828125
. 0.7978515625
▁Despite 6.5546875
▁the 1.552734375
▁immense 6.1484375
▁potential 1.9814453125
▁of 0.71533203125
▁this 1.30078125
▁revolution 3.49609375
ary 0.0173187255859375
▁treatment 2.830078125
, 0.482421875
▁the 1.6611328125
▁road 7.640625
▁to 0.66650390625
▁becoming 4.13671875
▁a 0.52587890625
▁block 5.125
b 0.07720947265625
uster 0.005275726318359375
▁drug 1.294921875
▁is 1.1669921875
▁filled 4.67578125
▁with 0.0086669921875
▁form 5.84765625
id 0.0006060600280761719
able 0.0017557144165039062
▁challeng 1.30078125
es 0.0009379386901855469
. 0.52978515625
<0x0A> 1.3662109375
Mar 4.40234375
im 2.22265625
ast 0.032440185546875
at 0.0035266876220703125
, 1.7001953125
▁an 2.732421875
▁innov 2.408203125
ative 0.03338623046875
▁bi 5.19140625
oph 2.478515625
arma 0.00804901123046875
ce 0.0254669189453125
ut 1.3589859008789062e-05
ical 0.0025615692138671875
▁break 8.0703125
through 0.00557708740234375
, 0.66162109375
▁a 4.23046875
ims 0.2548828125
▁to 0.010528564453125
▁transform 3.337890625
▁the 0.478515625
▁landscape 4.24609375
▁of 0.09442138671875
▁cancer 0.5478515625
▁treatment 0.61279296875
▁by 0.93408203125
▁comb 5.48046875
atting 0.9658203125
▁ag 4.90234375
gress 0.0240631103515625
ive 0.0118865966796875
▁tum 1.490234375
or 1.5322265625
▁growth 2.111328125
. 2.416015625
▁Design 5.640625
ed 0.009307861328125
▁to 0.369384765625
▁in 3.73828125
hib 0.034576416015625
it 0.0011920928955078125
▁the 1.052734375
▁activity 2.31640625
▁of 0.01221466064453125
▁en 4.6953125
zym 0.022125244140625
es 0.06103515625
▁responsible 2.921875
▁for 0.002002716064453125
▁the 1.55859375
▁spread 4.96484375
▁of 0.36865234375
▁cancer 0.36767578125
▁cells 0.548828125
, 0.284912109375
▁Mar 0.40673828125
im 0.007293701171875
ast 0.00507354736328125
at 0.0014801025390625
▁has 2.232421875
▁demonstrated 3.423828125
▁remarkable 2.375
▁effic 1.626953125
acy 5.3048133850097656e-05
▁in 0.43505859375
▁pre 1.9130859375
cl 0.2318115234375
in 1.7523765563964844e-05
ical 0.00044989585876464844
▁studies 1.017578125
▁and 1.5869140625
▁initial 4.78515625
▁human 2.54296875
▁tri 1.0185546875
als 4.863739013671875e-05
. 0.365478515625
<0x0A> 1.375
The 2.169921875
▁initial 5.45703125
▁clin 1.8291015625
ical 0.0014867782592773438
▁tri 0.87109375
als 4.017353057861328e-05
▁conducted 3.26953125
▁by 1.119140625
▁British 6.6484375
▁Bi 0.262939453125
ote 0.002124786376953125
ch 0.078857421875
▁Pl 0.2459716796875
c 0.0007147789001464844
▁yield 6.0
ed 0.03533935546875
▁optim 7.95703125
istic 0.10626220703125
▁results 0.11517333984375
, 0.98193359375
▁displaying 5.71875
▁significant 3.0078125
▁tum 2.880859375
or 0.0037326812744140625
▁shr 0.85009765625
ink 0.0367431640625
age 0.00482177734375
▁and 1.333984375
▁improved 3.23046875
▁patient 2.220703125
▁out 1.5400390625
comes 0.037567138671875
▁in 2.236328125
▁various 5.359375
▁cancer 1.5546875
▁types 0.7412109375
. 0.2484130859375
▁Data 6.796875
▁from 0.875
▁these 1.876953125
▁tri 1.3203125
als 2.4437904357910156e-05
▁indicated 4.16796875
▁that 0.36669921875
▁Mar 0.477783203125
im 0.0038738250732421875
ast 0.004756927490234375
at 0.0011873245239257812
▁effectively 3.91015625
▁cur 5.5390625
bed 0.298828125
▁cancer 2.298828125
▁cell 1.49609375
▁growth 0.39794921875
, 1.4111328125
▁reducing 3.45703125
▁the 1.3310546875
▁risk 2.708984375
▁of 0.0604248046875
▁met 2.900390625
ast 0.0003654956817626953
asis 0.1561279296875
▁and 0.57177734375
▁extending 3.162109375
▁patient 1.939453125
▁surv 0.298095703125
ival 0.0035076141357421875
▁rates 3.16015625
. 0.19189453125
<0x0A> 0.69580078125
Des 3.19921875
p 0.1710205078125
ite 0.0009312629699707031
▁these 1.357421875
▁prom 0.6044921875
ising 7.49826431274414e-05
▁out 3.412109375
comes 0.003269195556640625
, 0.0567626953125
▁significant 4.546875
▁obst 2.39453125
acles 0.0002925395965576172
▁lie 3.208984375
▁ahead 0.477294921875
▁for 1.10546875
▁British 0.8720703125
▁Bi 0.00830078125
ote 0.00042891502380371094
ch 0.0060272216796875
▁Pl 0.0794677734375
c 0.00021374225616455078
' 3.8359375
s 0.0015077590942382812
▁Mar 2.0234375
im 0.00490570068359375
ast 0.0037364959716796875
at 0.0004963874816894531
▁to 5.33984375
▁c 7.8359375
ement 0.3173828125
▁its 0.2509765625
▁position 1.16015625
▁as 0.2359619140625
▁a 0.131103515625
▁block 1.0908203125
b 0.0007963180541992188
uster 0.0017766952514648438
▁drug 0.53076171875
. 0.26171875
▁One 3.90234375
▁major 2.3359375
▁challenge 0.87744140625
▁is 1.763671875
▁the 0.84521484375
▁rig 6.63671875
orous 0.1597900390625
▁and 3.947265625
▁complex 2.462890625
▁process 3.421875
▁of 0.58935546875
▁obtain 1.51171875
ing 3.814697265625e-05
▁regul 1.375
atory 9.047985076904297e-05
▁appro 0.0753173828125
val 2.3365020751953125e-05
s 1.4443359375
. 1.6083984375
▁The 2.44140625
▁drug 3.03125
▁must 1.0087890625
▁under 1.314453125
go 0.00047206878662109375
▁extensive 1.408203125
▁testing 1.275390625
▁to 1.3779296875
▁ensure 1.40234375
▁its 1.6337890625
▁safety 0.262939453125
▁and 0.18212890625
▁effic 0.251708984375
acy 2.5510787963867188e-05
▁in 1.9619140625
▁larger 6.453125
▁patient 2.3984375
▁populations 0.1756591796875
. 0.8193359375
▁The 3.97265625
▁bi 6.1640625
ote 0.377685546875
ch 0.27783203125
▁company 1.11328125
▁anticip 8.0546875
ates 0.00489044189453125
▁facing 2.544921875
▁string 5.296875
ent 3.159046173095703e-05
▁scr 4.84375
ut 1.2159347534179688e-05
iny 0.0010623931884765625
▁from 0.357177734375
▁regul 0.408203125
atory 0.27392578125
▁bodies 1.197265625
▁such 3.259765625
▁as 0.0020351409912109375
▁the 0.0270233154296875
▁F 0.91552734375
DA 0.0011930465698242188
▁and 0.65625
▁the 1.669921875
▁European 1.9755859375
▁Medic 0.11572265625
ines 0.0026187896728515625
▁Agency 0.0101165771484375
▁( 1.3251953125
EMA 0.01038360595703125
). 0.71044921875
<0x0A> 0.59619140625
F 2.66015625
ur 0.05560302734375
ther 4.935264587402344e-05
more 0.267578125
, 0.00013887882232666016
▁competition 6.5
▁within 3.130859375
▁the 0.0340576171875
▁bi 1.6474609375
ote 0.191650390625
ch 0.1085205078125
▁industry 0.42529296875
▁is 0.31201171875
▁fier 0.97705078125
ce 0.0020236968994140625
. 0.79833984375
▁N 6.98828125
umer 0.0175018310546875
ous 0.00017786026000976562
▁ph 2.685546875
arma 0.0003590583801269531
ce 0.010345458984375
ut 1.430511474609375e-06
ical 0.0001049041748046875
▁gi 2.587890625
ants 3.910064697265625e-05
▁also 6.25390625
▁invest 5.703125
▁substantial 5.03515625
▁resources 0.61474609375
▁in 0.63671875
▁cancer 2.921875
▁research 1.3515625
▁and 0.775390625
▁development 0.41064453125
. 1.0
▁British 1.9384765625
▁Bi 0.003170013427734375
ote 7.784366607666016e-05
ch 0.004764556884765625
▁Pl 0.028228759765625
c 0.00034308433532714844
▁will 1.8359375
▁need 1.2255859375
▁to 0.0150299072265625
▁invest 3.67578125
▁in 1.8203125
▁market 3.029296875
ing 0.025543212890625
▁and 0.398193359375
▁commercial 4.21875
ization 0.09033203125
▁strateg 1.37890625
ies 2.9921531677246094e-05
▁to 0.45458984375
▁distinguish 5.0625
▁itself 0.64794921875
▁and 3.0390625
▁position 3.921875
▁Mar 0.66015625
im 0.0010929107666015625
ast 0.0023365020751953125
at 0.0001577138900756836
▁as 0.10528564453125
▁the 2.455078125
▁go 2.412109375
- 0.0015153884887695312
to 0.00016880035400390625
▁cancer 1.896484375
▁treatment 0.63720703125
. 0.6484375
<0x0A> 0.39892578125
An 4.55078125
other 0.1451416015625
▁hur 3.330078125
d 7.355213165283203e-05
le 5.4001808166503906e-05
▁to 2.197265625
▁overcome 0.654296875
▁is 0.2183837890625
▁fund 4.59765625
ing 0.08819580078125
. 0.34130859375
▁Develop 7.01953125
ing 0.016876220703125
▁and 2.267578125
▁bringing 3.349609375
▁a 0.7333984375
▁drug 2.771484375
▁to 0.09417724609375
▁market 0.0677490234375
▁is 1.5751953125
▁an 2.0859375
▁expensive 0.1453857421875
▁ende 1.4931640625
avor 2.682209014892578e-05
, 0.89306640625
▁requiring 2.130859375
▁substantial 1.7158203125
▁financial 3.2421875
▁backing 2.232421875
. 0.744140625
▁British 1.0478515625
▁Bi 0.0019054412841796875
ote 4.5180320739746094e-05
ch 0.0019855499267578125
▁Pl 0.022247314453125
c 0.00011456012725830078
▁will 1.0263671875
▁need 0.32373046875
▁to 0.079345703125
▁secure 1.3828125
▁additional 2.59375
▁invest 3.046875
ment 0.38525390625
▁to 0.55712890625
▁fin 1.6611328125
ance 0.0002617835998535156
▁continued 5.51171875
▁research 1.041015625
, 3.380859375
▁clin 1.41796875
ical 0.0004572868347167969
▁tri 0.057220458984375
als 1.6450881958007812e-05
, 0.08807373046875
▁and 0.09124755859375
▁the 3.087890625
▁production 4.13671875
▁scale 8.640625
- 0.68798828125
up 0.00934600830078125
▁necessary 2.142578125
▁for 1.7041015625
▁w 3.919921875
ides 0.0007615089416503906
p 0.002651214599609375
read 0.00025010108947753906
▁distribution 0.97900390625
. 0.2371826171875
<0x0A> 0.150146484375
Al 4.578125
though 0.0908203125
▁the 1.748046875
▁path 3.248046875
▁to 0.425048828125
▁block 4.56640625
b 0.0002887248992919922
uster 0.0068359375
▁status 0.75634765625
▁is 0.63525390625
▁challeng 2.146484375
ing 0.0003097057342529297
, 0.07281494140625
▁British 0.27978515625
▁Bi 0.0018033981323242188
ote 0.00012636184692382812
ch 0.0022640228271484375
▁Pl 0.016143798828125
c 0.00012981891632080078
▁remains 3.21875
▁und 3.54296875
eter 0.60498046875
red 8.797645568847656e-05
, 3.923828125
▁determined 3.544921875
▁to 0.0022258758544921875
▁navigate 7.96875
▁these 1.3681640625
▁hur 3.115234375
d 1.621246337890625e-05
les 0.0001327991485595703
▁and 0.374267578125
▁bring 0.96240234375
▁Mar 0.486572265625
im 0.0004105567932128906
ast 0.0017452239990234375
at 9.715557098388672e-05
▁to 0.0225830078125
▁patients 1.9384765625
▁glob 5.4453125
ally 0.0001163482666015625
. 0.1375732421875
▁With 1.2236328125
▁on 5.51171875
going 0.07330322265625
▁research 2.001953125
, 1.67578125
▁the 3.12109375
▁company 1.1328125
▁is 0.80517578125
▁optim 2.6953125
istic 0.0017986297607421875
▁that 0.57568359375
▁further 6.36328125
▁clin 0.98486328125
ical 0.0005140304565429688
▁tri 0.17919921875
als 1.7881393432617188e-06
▁will 0.46044921875
▁rein 7.28125
force 0.006542205810546875
▁the 0.732421875
▁drug 1.63671875
' 0.00728607177734375
s 0.0002899169921875
▁potential 2.8984375
▁as 1.4296875
▁a 0.07550048828125
▁game 2.87890625
- 0.047607421875
ch 0.0007977485656738281
anger 2.0859375
▁in 0.221435546875
▁the 0.9296875
▁fight 1.357421875
▁against 0.00934600830078125
▁cancer 0.02154541015625
. 0.03570556640625
<0x0A> 0.402587890625
In 3.509765625
▁conclusion 2.599609375
, 0.004150390625
▁British 0.418701171875
▁Bi 0.003173828125
ote 9.512901306152344e-05
ch 0.004184722900390625
▁Pl 0.01548004150390625
c 0.00022232532501220703
' 1.9404296875
s 0.0015621185302734375
▁cancer 6.48046875
▁drug 0.5634765625
, 0.85009765625
▁Mar 0.010711669921875
im 0.0015344619750976562
ast 0.0031986236572265625
at 0.00022470951080322266
, 0.047821044921875
▁offers 3.775390625
▁a 1.521484375
▁prom 0.469482421875
ising 5.3763389587402344e-05
▁break 4.25
through 0.0032825469970703125
▁in 0.360107421875
▁cancer 1.3779296875
▁treatment 0.15869140625
. 0.275634765625
▁While 4.45703125
▁hur 7.359375
d 7.3909759521484375e-06
les 0.05029296875
▁such 3.95703125
▁as 0.0024280548095703125
▁regul 0.63916015625
atory 0.00012433528900146484
▁appro 0.10455322265625
val 6.783008575439453e-05
s 0.51904296875
, 1.482421875
▁competition 1.0068359375
, 0.66455078125
▁and 0.09271240234375
▁fund 0.071533203125
ing 0.007793426513671875
▁may 3.125
▁present 1.9521484375
▁challeng 0.50390625
es 0.0026531219482421875
, 0.40673828125
▁the 0.453857421875
▁company 0.62255859375
' 2.447265625
s 0.00010395050048828125
▁un 3.09375
wa 0.11700439453125
ver 7.164478302001953e-05
ing 0.00012981891632080078
▁commit 0.470458984375
ment 0.0001996755599975586
▁to 0.193359375
▁innov 2.1015625
ation 0.0889892578125
▁suggests 7.47265625
▁that 0.34326171875
▁Mar 0.59375
im 0.0011625289916992188
ast 0.0016908645629882812
at 0.00011038780212402344
▁has 0.6708984375
▁the 0.351318359375
▁potential 0.0360107421875
▁to 0.00740814208984375
▁revolution 2.421875
ize 0.0005550384521484375
▁cancer 0.95947265625
▁ther 3.78515625
apy 0.03570556640625
▁and 2.34375
▁posit 5.23828125
ively 0.000629425048828125
▁impact 0.136474609375
▁count 3.904296875
less 3.0517578125e-05
▁lives 0.6083984375
. 0.07891845703125
